This morning, Gov. Terry Branstad, Lt. Gov. Kim Reynolds, Executive Director of the Governor's STEM (Science, Technology, Engineering and Mathematics) Advisory Council Jeff Weld, and Waukee second-grade teacher Heather Anderson, accompanied by five of her students, discussed results from the 2015-2016 independent evaluation that measures the success of the STEM Council's efforts to advance STEM education and economic development across Iowa.
Highlights of the 306-page Iowa STEM evaluation include:
In the early 2000s, cystic fibrosis researchers were frustrated with available mouse models of the disease. The mice carried the mutant version of the cystic fibrosis transmembrane conductance regulator (CFTR) gene that causes the disease in people, but the animals didn’t develop the mucus-coated lungs, coughing, or breathing difficulty observed in human patients. Researchers at the University of Iowa (UI) thought they might have a solution—genetically modified miniature pigs.
UI Research Park-based company employs more than 800 worldwide
BY: STEPHEN PRADARELLI | 2013.10.29 | 12:12 PM
Integrated DNA Technologies' headquarters at the UI Research Park.
A University of Iowa spin-off company, Integrated DNA Technologies, is one of 100 businesses highlighted in a new national report by The Science Coalition demonstrating how federally funded research fuels American innovation and economic growth.
Integrated DNA Technologies (IDT) has acquired MBiotech, a Seoul, South Korea-based distributor of IDT products.
Coralville-based IDT said MBiotech has made IDT's brand well-known throughout the South Korean peninsula. The company also distributes products for other manufacturers, which include reagents, enzymes, kits, consumables and lab equipment.
Terms of the sale were not disclosed. Following the acquisition, IDT will continue MBiotech's distribution of other manufacturers' product and plans to keep day-to-day operations unchanged, IDT said in a June 2 announcement.
By Tom Snee 4/18/16
A University of Iowa spinout company that invented a device allowing physically impaired patients to communicate with health care providers expects to launch its product this summer after receiving significant investor interest during clinical trials.
Coralville-based KemPharm's shares are ending the week on a strong note following a big price spike on Wednesday.
The company's chief focus is on developing painkillers that, unlike conventional opiod painkillers, are non-addictive. The FDA accepted an Investigational New Drug Application from KemPharm for KP511, an abuse-deterrent extended release opioid painkiller, at the end of last month.
President Obama announced government plans to spend some $1 billion to fight the opioid addiction crisis on March 29 at the National Rx Drug Abuse and Heroid Summit in Atlanta.